Intressanta studier med BOSULIF (bosutinib)Â
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND studyÂ
Hochaus et al, Leukemia, 2020 Aug;34(8):2125-2137Â
https://pubmed.ncbi.nlm.nih.gov/32572189/Â
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemiaÂ
Brümmendorf et al Ann Hematol, 2020 Jun;99(6):1241-1249Â
https://pubmed.ncbi.nlm.nih.gov/32307568/Â
Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond TrialÂ
Gambacorti-Passerini et al, Blood, Volume 138, Supplement 1, 23 November 2021, Page1475
https://ashpublications.org/blood/article/138/Supplement%201/1475/480608/Efficacy-and-Safety-of-Bosutinib-in-Previously
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinibÂ
Cortes JE, et al, Blood. 2011 Oct 27; 118(17): 4567–4576Â
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916618/Â
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureÂ
Khoury HJ, et al, Blood, 2012 Apr 12;119(15):3403-12Â
https://pubmed.ncbi.nlm.nih.gov/22371878/Â
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE TrialÂ
Cortes JE, et al, J Clin Oncol, 2018 Jan 20;36(3):231-237Â
https://pubmed.ncbi.nlm.nih.gov/29091516Â